Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5698 Target Snapshot

NUAK family SNF1-like kinase 2 · SINGLE PROTEIN · Homo sapiens

563Compounds
196Assays
12Approved Drugs
380.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9H093. Use UniProt Q9H093 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9H093 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NUAK family SNF1-like kinase 2 as ChEMBL target CHEMBL5698, mapped to UniProt Q9H093. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NUAK family SNF1-like kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5698
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H093
NUAK family SNF1-like kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NUAK family SNF1-like kinase 2 is the right protein anchor across sources, using UniProt Q9H093 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNUAK family SNF1-like kinase 2
UniProt AccessionQ9H093
Component TypeProtein
Sequence Length628 aa

NUAK family SNF1-like kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as NUAK family SNF1-like kinase 2, mapped to UniProt Q9H093. Sequence length is 628 aa.

Mapped IDQ9H093
Review nameNUAK family SNF1-like kinase 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
8
Phase III
6
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC5020.0
EC501.0
KD359.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 10.07 Kd 0.086 Preclinical
CHEMBL3904602 9.15 Kd 0.7 Clinical
CHEMBL603469 9.0 Kd 1.0 Clinical
CHEMBL509032 8.92 Kd 1.2 Preclinical
CHEMBL388978 8.79 IC50 1.62 Preclinical
CHEMBL270995 8.52 Kd 3.0 Clinical
CHEMBL4284499 8.46 Kd 3.5 Preclinical
CHEMBL482967 8.15 Kd 7.0 Preclinical
CHEMBL4465866 8.0 Kd 10.0 Preclinical
CHEMBL1229592 8.0 Kd 10.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
10
5.5
16
6.0
16
6.5
11
7.0
7
7.5
4
8.0
6
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

196
Total Assays
61
Tested Compounds
1
Assay Types
Binding — 196 assays, 61 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 147 47 6.9
assay format 30 2 7.7
cell-based format 18 4 7.0
subcellular format 1 8 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine